New combo therapy targets tough leukemia mutations
NCT ID NCT05453903
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 participants, including some teens, will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Albert Einstein College Of Medicine
New York, New York, 10461, United States
-
Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
Bologna, 40138, Italy
-
CHU de Tours - Hôpital de Bretonneau
Tours, 37044, France
-
Charite Universitaetsmedizin Berlin
Berlin, 13353, Germany
-
Christie Hospital NHS Trust
Manchester, M20 4BX, United Kingdom
-
Chu Rennes Hopital Pontchaillou
Rennes, 35033, France
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 8035, Spain
-
Hosp. de La Santa Creu I Sant Pau
Barcelona, 08025, Spain
-
IRCCS Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, 31100, France
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, 47014, Italy
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Monash Medical Centre
Clayton, 3168, Australia
-
Novant Health
Charlotte, North Carolina, 28204, United States
-
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, 27103, United States
-
Oxford University Hospitals NHS Trust
Oxfordshire, OX3 7LE, United Kingdom
-
Peter MacCallum Cancer Centre
Melbourne, 3000, Australia
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G 1Z5, Canada
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, 01307, Germany
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University College London Hospitals NHSFT
London, NW1 2PG, United Kingdom
-
Westmead Hospital
Westmead, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a fourth drug tip the scales against an aggressive leukemia?
- Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
- New drug combination targets rare childhood leukemia that resists standard treatment
- New combo aims to boost survival in older AML patients
- New combo therapy for AML enters early human testing
- New hope for older AML patients: triple drug combo aims to control disease and prevent relapse